ImmunoGen Lead Drug Gets Nod For Accelerated Approval Pathway (Revised)
Zacks Investment Research | Dec 24, 2019 07:12AM ET
ImmunoGen, Inc. (NASDAQ:IMGN) announced that the FDA has advised to conduct a new single-arm pivotal study, which can support accelerated approval for its lead candidate, mirvetuximab soravtansine, in ovarian cancer. We note that the FDA had recommended a new monotherapy study on the candidate in May, following the failure of phase III study – FORWARD 1.
Based on the FDA’s guidance, the company is planning to initiate a pivotal study, SORAYA, in patients with platinum-resistant ovarian cancer whose tumors express high levels of FR alpha and who have received prior treatment with Roche’s (OTC:RHHBY) Avastin (bevacizumab). The company is expected to start enrolling patients in the SORAYA study by the next quarter, with top-line data expected to be available by mid-2021. The company is anticipating to file a regulatory application in the second half of 2021, seeking accelerated approval for mirvetuximab soravtansine, if the study is completed successfully.
Shares of ImmunoGen gained 18.8% on Dec 17 following the announcement. Investors cheered the news as a single-arm, pivotal study is likely to reduce the time to get an approval for mirvetuximab soravtansine. The company’s shares have gained 13.8% so far this year compared with the industry ’s increase of 13.2%.
Please note that the company announced in March that its FORWARD 1 study failed to meet the primary endpoint of progression-free survival (“PFS”). The FORWARD 1 study evaluated the efficacy of mirvetuximab soravtansine as a single-agent therapy compared to chemotherapy for the treatment of patients with platinum-resistant ovarian cancer whose tumors express high or medium levels of FR alpha and who have received up to three prior treatment regimens. However, the overall response rate (“ORR”) for the candidate was higher tin the study compared to patients who were treated with chemotherapy.
The SORAYA study will evaluate the candidate in patients with platinum-resistant ovarian cancer whose tumors express high levels of FRα and have received up to three prior treatments, including at least one with Avastin. However, the primary endpoint of the study will be ORR instead of PFS as in FORWARD 1 study.
Meanwhile, the company stated on its third-quarter earnings call that it has met with the FDA to review the design of a phase III study – MIRASOL – which will compare mirvetuximab soravtansine head-to-head with single agent chemotherapy in platinum-resistant ovarian cancer patients with high folate receptor alpha expression. The company expects to initiate enrollment in the study by the year end. It is planning to use this study as a confirmatory study, which will support continued approval for mirvetuximab soravtansine, if it gets accelerated approval based on SORAYA study data. Top-line data from MIRASOL study is anticipated in the first half of 2022.
A phase Ib/II FORWARD II study is evaluating mirvetuximab soravtansine in combination with Avastin or Merck’s (NYSE:MRK) Keytruda for treating cancerous tumors especially with medium or high FRα expression levels.
Apart from mirvetuximab soravtansine, the company is also developing another pipeline candidate, IMGN632, in several early- to mid-stage studies as monotherapy or in combination with Celgene’s Vidaza or AbbVie (NYSE:ABBV) /Roche’s Venclexta for treating acute myeloid leukemia and other oncology indications.
Get The News You Want
ImmunoGen, Inc. Price
Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.